Fiche centre
TG Therapeutics Investigational Trial Site
Cleveland — United States
Essais liés4clinical trials
VilleClevelandlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03379051
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Venetoclax | SEP | Phase 1/2 | NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | TERMINATED |
| ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | SEP | À vérifier | NCT06433752 | ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT05877963 | ENHANCE — Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | RECRUITING |
| Azercabtagene zapreleucel (azer-cel) | Myasthénie | Phase 1 | NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | RECRUITING |